Roederer MW, O'Connor SK, Ferreri SP. Roederer M.W., O'Connor S.K., Ferreri S.P. Roederer, Mary W., et al.Chapter 9. Public Access to Pharmacogenomic Testing and Patient Counseling. In: Bertino JS, Jr, DeVane C, Fuhr U, Kashuba AD, Ma JD. Bertino J.S., Jr, DeVane C, Fuhr U, Kashuba A.D., Ma J.D. Eds. Joseph S. Bertino, Jr, et al.eds. Pharmacogenomics: An Introduction and Clinical Perspective New York, NY: McGraw-Hill; 2013. http://accesspharmacy.mhmedical.com/content.aspx?bookid=511&sectionid=40849377. Accessed April 26, 2019.
Roederer MW, O'Connor SK, Ferreri SP. Roederer M.W., O'Connor S.K., Ferreri S.P. Roederer, Mary W., et al.. "Chapter 9. Public Access to Pharmacogenomic Testing and Patient Counseling." Pharmacogenomics: An Introduction and Clinical Perspective Bertino JS, Jr, DeVane C, Fuhr U, Kashuba AD, Ma JD. Bertino J.S., Jr, DeVane C, Fuhr U, Kashuba A.D., Ma J.D. Eds. Joseph S. Bertino, Jr, et al. New York, NY: McGraw-Hill, 2013, http://accesspharmacy.mhmedical.com/content.aspx?bookid=511&sectionid=40849377.
Compare and contrast the patient and healthcare professional access to pharmacogenomic tests.
Review the roles of health care professionals in patient counseling regarding pharmacogenomic tests.
Examine the pharmacist-centered patient counseling model and the integration of pharmacogenomic information.
Explore the application of pharmacogenomic data to patient vignettes.
There is an eminent need for health care professionals to be prepared to integrate pharmacogenomics into clinical care. There is both growing scientific evidence and an interest of the lay press regarding individualized, tailored, or personalized medicine. As a new area of medicine, pharmacogenomics poses many challenges as well as opportunities. For health care professionals, there are challenges in obtaining a baseline understanding of the relevance of pharmacogenomics and maintaining a current understanding of the evidence supporting pharmacogenomics as it relates to patient care. For patients, there are challenges to being willing to provide genetic information for optimizing their medication therapy and to distinguish the less reputable direct-to-consumer options for genetic testing. Opportunities shared by patients and professionals include an understanding that the “one dose fits all” approach is flawed and that pharmacogenomics is one tool to improve our ability to provide the right drug in the right dose to the right patient.